- Genetic testing, enabling the identification of genetic disorders, disease predisposition, and ancestry, is becoming an essential component of personalized medicine and preventive healthcare across both clinical and direct-to-consumer applications due to its diagnostic accuracy, rapid technological advancements, and increasing affordability
- The escalating demand for genetic testing is primarily fueled by the growing prevalence of chronic and hereditary diseases, rising awareness of early disease detection, and expanding use of genomics in oncology, prenatal screening, and pharmacogenomics
- North America dominated the genetic testing market with the largest revenue share of 48.1% in 2024, driven by a well-established healthcare infrastructure, favorable reimbursement policies, and the presence of leading genetic testing companies, with the U.S. at the forefront due to high testing volumes and adoption of next-generation sequencing technologies
- Asia-Pacific is expected to be the fastest growing region in the genetic testing market during the forecast period due to increasing healthcare expenditures, growing awareness about genetic diseases, and expanding government initiatives to promote genomic research
- The predictive testing segment dominated the genetic testing market with a market share of 37.3% in 2024, driven by its critical role in early diagnosis, risk assessment, and personalized treatment planning across various disease areas
